[go: up one dir, main page]

MA28175A1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA28175A1
MA28175A1 MA29053A MA29053A MA28175A1 MA 28175 A1 MA28175 A1 MA 28175A1 MA 29053 A MA29053 A MA 29053A MA 29053 A MA29053 A MA 29053A MA 28175 A1 MA28175 A1 MA 28175A1
Authority
MA
Morocco
Prior art keywords
disease
relates
cardiac
flbrose
hyperaldosteronism
Prior art date
Application number
MA29053A
Other languages
English (en)
Inventor
Daniel Kaspar Baeschlin
Jurgen Klaus Maibaum
Holger Sellner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28175A1 publication Critical patent/MA28175A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés amides d'acide -amino- -hydroxy- -aryl-alkanoïque représentés par la formule (I) et les sels de ceux-ci, présentant des propriétés d'inhibition de la rénine. Cette invention concerne également des compositions pharmaceutiques comprenant ces composés, ainsi que des méthodes consistant à les administrer pour traiter l'hypertension, l'athérosclérose, un syndrome coronarien instable, une insuffisance cardiaque congestive, une hypertrophie cardiaque, une librose cardiaque, un post-infarctus en cas de cardiomyopathie, un dysfonctionnement diastoiique, une maladie rénale chronique, une flbrose hépatique, des complications entraînées par des diabètes, telles qu'une néphropathie, une vasculopathie, et une neuropahtie, des maladies des vaisseaux coronariens, une resténose après une angioplastie, une augmentation de la pression intra-occulaire, un glaucome, une croissance vasculaire anormale, un hyperaldosteronisme, une déficience cognitive, la maladie d'Alzheimer, la démence, les états d'anxiété et les troubles cognilifs.
MA29053A 2003-11-26 2006-05-24 Composes organiques MA28175A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52537403P 2003-11-26 2003-11-26

Publications (1)

Publication Number Publication Date
MA28175A1 true MA28175A1 (fr) 2006-09-01

Family

ID=34632978

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29053A MA28175A1 (fr) 2003-11-26 2006-05-24 Composes organiques

Country Status (18)

Country Link
US (3) US7582782B2 (fr)
EP (2) EP2266951A1 (fr)
JP (1) JP4884230B2 (fr)
KR (1) KR20060111530A (fr)
CN (2) CN102260188A (fr)
AU (2) AU2004293178B8 (fr)
BR (1) BRPI0417017A (fr)
CA (1) CA2600973C (fr)
CO (1) CO5700726A2 (fr)
EC (1) ECSP066561A (fr)
IL (1) IL175435A0 (fr)
IS (1) IS8513A (fr)
MA (1) MA28175A1 (fr)
NO (1) NO20062968L (fr)
RU (1) RU2413716C2 (fr)
TN (1) TNSN06156A1 (fr)
WO (1) WO2005051895A1 (fr)
ZA (1) ZA200602993B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004293178B8 (en) * 2003-11-26 2009-01-08 Novartis Ag Organic compounds
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
EP1799199B1 (fr) * 2004-10-08 2012-03-28 Novartis AG Utilisation d'inhibiteurs de renine pour la prevention ou le traitement du dysfonctionnement diastolique ou de la cardiopathie diastolique
TW200631929A (en) * 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
EP1856032A1 (fr) * 2005-03-11 2007-11-21 Speedel Experimenta AG Alcanamides heterocycliques substitues utiles comme inhibiteurs de la renine
GB0505969D0 (en) * 2005-03-23 2005-04-27 Novartis Ag Organic compounds
CN101262864A (zh) * 2005-09-17 2008-09-10 斯皮德尔实验股份公司 饱和o-杂环取代的烷酰胺
EP1764098A1 (fr) * 2005-09-17 2007-03-21 Speedel Experimenta AG Dérivés de diaminoalcols et leur utilization pour le traitement de la malaria, de la maladie d'Alzheimer et du SIDA
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
WO2007048027A2 (fr) * 2005-10-21 2007-04-26 Novartis Ag Combinaison de composes organiques
GB2431648A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431653A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431640A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431641A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431646A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431642A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431645A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
EP2420491B1 (fr) 2005-12-30 2013-07-03 Novartis AG Dérivés de pipéridine 3,5-substitués en tant qu'inhibiteurs de rénine
GB0611697D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
GB0611696D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
EP1872780A3 (fr) * 2006-06-14 2008-04-30 Speedel Experimenta AG Omega-phényloctanamides en tant que composés thérapeutiques
EP1867329A3 (fr) * 2006-06-14 2008-05-07 Speedel Experimenta AG 5-amino-4-hydroxy-2-isopropyl-7-[4-méthoxy-3-(3-méthoxypropoxy)benzyl]-8-méthylnonanamides en tant que composés thérapeutiques
WO2007148775A1 (fr) * 2006-06-23 2007-12-27 Daiichi Sankyo Company, Limited Composé à chaîne aminée
KR20090031517A (ko) 2006-06-23 2009-03-26 다이이찌 산쿄 가부시키가이샤 고리형 아민 화합물
EP1958666A1 (fr) * 2007-02-13 2008-08-20 Speedel Experimenta AG Alcanamides substitués hétérocycliques en tant que composants thérapeutiques
BRPI0813900A2 (pt) 2007-06-25 2014-12-30 Novartis Ag Derivados de n5-(2-etoxietil)-n3-(2-piridinil)-3,5-piperidinodicarboxa mida para uso como inibidores de renina
JP5223686B2 (ja) * 2009-01-07 2013-06-26 株式会社リコー 撮像装置および撮像方法
US8779198B2 (en) 2009-08-11 2014-07-15 Novartis Ag Ring opening of lactones and lactams
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CN102161627A (zh) * 2011-02-24 2011-08-24 中国药科大学 ω-(N取代-氨基烷基)辛酰胺
WO2012161173A1 (fr) * 2011-05-23 2012-11-29 第一三共株式会社 Composé d'amide substitué
WO2012165314A1 (fr) * 2011-05-27 2012-12-06 第一三共株式会社 Composé amide
WO2013045505A1 (fr) 2011-09-28 2013-04-04 Novartis Ag Biomarqueurs pour traitement combiné par des agents sraa
EP2810644A1 (fr) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Formulation orale pour le traitement de maladies cardiovasculaires

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88619A0 (en) * 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
IL96942A (en) * 1990-01-31 1995-01-24 Abbott Lab A pharmaceutical mixture containing a history of amide prevents renin
JPH0532602A (ja) * 1991-07-26 1993-02-09 Terumo Corp ナフチルメチルアミン誘導体及びこれを含有するレニン阻害剤
JPH06199891A (ja) * 1992-09-18 1994-07-19 Japan Tobacco Inc レニン阻害活性を有するアルコール誘導体及びその用途
DE4300388C2 (de) * 1993-01-09 1995-03-16 Metallgesellschaft Ag Verfahren zur kontinuierlichen Einstellung und Regelung des pH-Wertes einer sauren Flüssigkeit, bei dem die kontinuierliche Messung des pH-Wertes mit einer Glaselektrode erfolgt
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2003103653A1 (fr) 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methodes de traitement de la maladie d'alzheimer par des amides d'acide aryl alcanoique
AU2004293178B8 (en) * 2003-11-26 2009-01-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ZA200602993B (en) 2008-04-30
CO5700726A2 (es) 2006-11-30
US7851642B2 (en) 2010-12-14
US20090253701A1 (en) 2009-10-08
JP2007512283A (ja) 2007-05-17
WO2005051895A8 (fr) 2006-07-20
IS8513A (is) 2006-06-19
KR20060111530A (ko) 2006-10-27
IL175435A0 (en) 2006-09-05
US20070135498A1 (en) 2007-06-14
AU2004293178B2 (en) 2008-12-11
US20090253703A1 (en) 2009-10-08
US7582782B2 (en) 2009-09-01
ECSP066561A (es) 2006-10-17
WO2005051895A1 (fr) 2005-06-09
CN1882528A (zh) 2006-12-20
BRPI0417017A (pt) 2007-02-21
AU2004293178A1 (en) 2005-06-09
AU2009200957B2 (en) 2011-09-01
TNSN06156A1 (en) 2007-11-15
EP1689702B1 (fr) 2013-01-30
CA2600973C (fr) 2012-08-07
RU2413716C2 (ru) 2011-03-10
RU2006122636A (ru) 2008-01-27
EP1689702A1 (fr) 2006-08-16
AU2009200957A1 (en) 2009-04-02
CN102260188A (zh) 2011-11-30
US7919529B2 (en) 2011-04-05
JP4884230B2 (ja) 2012-02-29
EP2266951A1 (fr) 2010-12-29
CA2600973A1 (fr) 2005-06-09
NO20062968L (no) 2006-08-28
AU2004293178B8 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
MA28175A1 (fr) Composes organiques
FI66860B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-1-imidazolylalkyl)indolderivat
TNSN05037A1 (fr) Derives heterobiaryliques servant d'inhibiteurs de metalloproteinases de matrice
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
MA29148B1 (fr) Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme
MA26946A1 (fr) Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases.
MA29909B1 (fr) Derives de pyridazine
MA30360B1 (fr) Dérivés pyrimidiniques utilisés comme inhibiteurs de la pi3k
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
CH620925A5 (fr)
WO2006028957A8 (fr) Derives de 4, 6-dialkoxy-cinnoline substitues en position 4 en tant qu'inhibiteurs de phospodiesterase 10 pour le traitement de syndromes psychiatriques ou neurologiques
WO2004033431A3 (fr) Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme
MA29775B1 (fr) Derives de pyrazolone
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
WO1999054320A1 (fr) Nouveaux amides heterocycliquement substitues a action de proteases de cysteine
MA29566B1 (fr) Composes chimiques
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
RU2374228C2 (ru) Производные 4-фенилпиперидина в качестве ингибиторов ренина
MA35875B1 (fr) Dérivés d'aza-adamantane et leurs utilisations
NO20062509L (no) Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav
EP1446402B1 (fr) Derives de 2-amino-4-heteroarylethyl thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
MA27716A1 (fr) 4-aminopyrimidine-5-one
TNSN07355A1 (fr) Derives d'aryl-1,4-pyrazine substitues
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
US5650521A (en) Pyrrolidine derivatives